Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
12 min read
Rhabdomyosarcoma of the Orbit Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Rhabdomyosarcoma of the Orbit in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Nemaline Myopathy 4 Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
27 August 2026
Evaluate Nemaline Myopathy 4 with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
8 min read
NCT07482657 Zelicapavir Respiratory Syncytial Virus Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07482657 clinical trial report covering Zelicapavir, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07485296 Pembrolizumab Recurrent Squamous Cell Carcinoma of the Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07485296 clinical trial report covering Pembrolizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600120829 Recombinant human endostatin(The Children's Hospital) Advanced Malignant Thoracic Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
ChiCTR2600120829 clinical trial report covering Recombinant human endostatin(The Children's Hospital), Phase 2, endpoints, sponsor, geography, readout timi
Latest Hotspot
8 min read
NCT07486310 Doxorubicin Hydrochloride Advanced gastric carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07486310 clinical trial report covering Doxorubicin Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600120859 Sintilimab Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
ChiCTR2600120859 clinical trial report covering Sintilimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260955 Recombinant human interleukin-1 receptor antagonist(General Regeneratives) Arthritis, Gouty Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
CTR20260955 clinical trial report covering Recombinant human interleukin-1 receptor antagonist(General Regeneratives), Phase 2, endpoints, sponsor, geograp
Latest Hotspot
8 min read
ChiCTR2600120886 Pucotenlimab Laryngeal Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
ChiCTR2600120886 clinical trial report covering Pucotenlimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07484724 JS-212 Advanced Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07484724 clinical trial report covering JS-212, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07485647 Lenalidomide Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07485647 clinical trial report covering Lenalidomide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07484906 Psilocybin Suicidal Ideation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07484906 clinical trial report covering Psilocybin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.